Lynch Thomas P. sold $2.0M of BLLN

Lynch Thomas P. (See Remarks) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $99.99 ($96.47–$101.41, $2.00M total) across 13 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lynch Thomas P.
Published Sep 10, 2026, 11:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 11:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be viewed as a bearish signal by some traders.

02

Market read

Primary insider sale news for a micro‑cap; modest trading relevance.

03

What to watch

Potential upcoming clinical data releases that may offset the negative signal.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑08

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Officer Lynch Thomas P. sold $2.0M of BLLN shares via a 10b5-1 plan, reducing his stake to 700 shares.

Expected impact

Potential short-term pressure on BLLN price, limited to a few cents.

Evidence & confidence

Form 4 is a primary disclosure; $2M sale by an officer is material for a micro‑cap but unlikely to move the stock dramatically.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited to investors tracking BLLN.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • BillionToOne, Inc.

    Biotech firm listed on NASDAQ under ticker BLLN.

  • Lynch Thomas P.

    Officer of BillionToOne, executing a pre‑arranged 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.